原型快速衣原体和淋球菌重组酶聚合酶扩增检测的诊断准确性:多中心横断面临床前评价
这项前瞻性多中心研究在三个英格兰性健康诊所评估了15分钟运行时间的重组酶聚合酶扩增原型即时检测对沙眼衣原体(CT)和淋病奈瑟菌(NG)的准确性。392名男性和395名女性提供了自采阴道拭子或首段尿样本,结果显示所有样本类型和两种病原体的特异性和阳性预测值均为100%,仅男性CT首段尿除外(特异性99.7%,阳性预测值97.1%)。CT灵敏度在首段尿和自采阴道拭子中均≥94.3%,NG在首段尿中灵敏度和阴性预测值均为100%。作者认为该原型检测性能优异,符合若干世界卫生组织ASSURED标准,进一步开发和商业化后可能对临床实践和公共卫生产生积极影响。
要点
- 原型15分钟重组酶聚合酶扩增检测对CT和NG的特异性和阳性预测值几乎均为100%。
- CT灵敏度在首段尿和自采阴道拭子中≥94.3%,女性首段尿为100%。
- NG在男性和女性首段尿中灵敏度和阴性预测值均为100%。
核心结论
- 该原型检测性能优异,与当前使用的核酸扩增检测相当,并符合若干世界卫生组织ASSURED标准。
- 其快速性且不损失性能提示,一旦进一步开发和商业化,该检测可能对临床实践和公共卫生产生积极影响。
研究设计与样本
- 前瞻性多中心研究,纳入三个英格兰性健康诊所的有症状和无症状患者。
- 研究对象提供额外的自采阴道拭子(女性)和首段尿等分样本(女性和男性)。
- 样本处理对常规诊所CT/NG核酸扩增检测结果设盲,不一致结果用Cepheid CT/NG GeneXpert解决。
- 392名男性和395名女性参与者的重组酶聚合酶扩增和常规诊所核酸扩增检测结果均可获得。
主要发现
- CT阳性率:男性首段尿8.9%(35/392),女性首段尿7.3%(29/395),自采阴道拭子7.1%(28/395)。
- NG阳性率:男性首段尿3.1%(12/392),女性首段尿0.8%(3/395),自采阴道拭子0.8%(3/395)。
- 所有样本类型和两种病原体的特异性和阳性预测值均为100%,仅男性CT首段尿例外:特异性99.7%(95%CI 98.4-100.0;356/357),阳性预测值97.1%(95%CI 84.7-99.9;33/34)。
- CT灵敏度在首段尿和自采阴道拭子中≥94.3%;女性首段尿CT灵敏度(100%;95%CI 88.1-100;29/29)高于自采阴道拭子(96.4%;95%CI 81.7-99.9;27/28)。
- NG在男性和女性首段尿中灵敏度和阴性预测值均为100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rapid and accurate sexually transmitted infection diagnosis can reduce onward transmission and improve treatment efficacy. We evaluated the accuracy of a 15-minute run-time recombinase polymerase amplification-based prototype point-of-care test (TwistDx) for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). METHODS: Prospective, multicentre study of symptomatic and asymptomatic patients attending three English sexual health clinics. Research samples provided were additional self-collected vulvovaginal swab (SCVS) (female participants) and first-catch urine (FCU) aliquot (female and male participants). Samples were processed blind to the comparator (routine clinic CT/NG nucleic acid amplification test (NAAT)) results. Discrepancies were resolved using Cepheid CT/NG GeneXpert. RESULTS: Both recombinase polymerase amplification and routine clinic NAAT results were available for 392 male and 395 female participants. CT positivity was 8.9% (35/392) (male FCU), 7.3% (29/395) (female FCU) and 7.1% (28/395) (SCVS). Corresponding NG positivity was 3.1% (12/392), 0.8% (3/395) and 0.8% (3/395). Specificity and positive predictive values were 100% for all sample types and both organisms, except male CT FCU (99.7% specificity (95% confidence interval (CI) 98.4-100.0; 356/357), 97.1% positive predictive value (95% CI 84.7-99.9; 33/34)). For CT, sensitivity was ≥94.3% for FCU and SCVS. CT sensitivity for female FCU was higher (100%; 95% CI, 88.1-100; 29/29) than for SCVS (96.4%; 95% CI, 81.7-99.9; 27/28). NG sensitivity and negative predictive values were 100% in FCU (male and female). CONCLUSIONS: This prototype test has excellent performance characteristics, comparable to currently used NAATs, and fulfils several World Health Organization ASSURED criteria. Its rapidity without loss of performance suggests that once further developed and commercialized, this test could positively affect clinical practice and public health.
引用
- Harding-Esch EM, Fuller SS, Chow SC, et al. Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation. Clin Microbiol Infect. 2018. PMID: 29906594. doi:10.1016/j.cmi.2018.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。